Table 1 Patient, disease, and treatment characteristics stratified by BRCA status (n = 61)
From: Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
| Characteristics | BRCA mutant n = 25 (41%) | BRCA wild type n = 36 (59%) | P-Value* | |
|---|---|---|---|---|
| N (Frequency) | N (Frequency) | |||
| Age at diagnosis | ||||
| Median (IQR) | 50 (43–56) | 55 (46–66) | 0.13 | |
| Age ≤ 50 | 14 (56) | 15 (41.7) | 0.27 | |
| Positive personal history of cancer | 5 (20) | 1 (2.9) | 0.04 | |
| Positive family history of cancer | 7 (28) | 2 (5.6) | 0.02 | |
| Presence of comorbidities* | 19 (76) | 24 (66.7) | 0.43 | |
| Histology | High-grade serous | 25 (100) | 35 (97.1) | 0.39 |
| Endometrioid | 1 (2.9) | |||
| High grade FIGO stage | 25 (100) | 34 (94.4) | 0.48 | |
| Stage 1 | 6 | 3 | 0.65 | |
| IA | 2 | 0 | ||
| IB | 2 | 1 | ||
| IC | 2 | 2 | ||
| Stage 2 | 1 | 4 | ||
| IIA | 1 | 1 | ||
| IIB | 0 | 3 | ||
| Stage 3 | 15 (58) | 21 (55) | ||
| IIIA | 0 | 2 | ||
| IIIB | 1 | 2 | ||
| IIIC | 14 | 17 | ||
| Stage 4 | 4 | 10 | ||
| High CA125 (> 35) | 20 (80) | 26 (72.2) | 0.46 | |
| Initial management | PDS | 12 (48) | 18 (50) | 0.87 |
| NAC | 13 (52) | 18 (50) | ||
| No. of lines, median (IQR) | 3 (1–5) | 3 (2–4.75) | 0.79 | |
| Lines of treatment | ||||
| First line (n = 61) | (n = 25) | (n = 18) | ||
| PBC Non PBC | 100% | 100% | 0.26 | |
| Second line (n = 49) | (n = 18) | (n = 31) | ||
| PBC | 88.9 | 83.4 | 0.79 | |
| Non PBC | 11.1 | 16.6 | ||
| Third line (n = 39) | (n = 13) | (n = 26) | ||
| PBC | 73.1 | 64 | 0.42 | |
| Non PBC | 26.9 | 36 | ||
| Fourth line (n = 23) | (n = 10) | (n = 13) | ||
| PBC | 50% | 23.1% | 0.38 | |
| Non PBC | 50% | 76.9% | ||
| Fifth line (n = 13) | (n = 7) | (n = 5) | ||
| PBC | – | – | 0.68 | |
| Non PBC | 100% | 100% | ||